Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Discover a study where findings revealed that using the new device significantly decreased both total and hourly scratch ...

Bsense Bio Therapeutics Ltd. has disclosed new potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators and transient receptor potential cation channel subfamily V member 1 (TRPV1 ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, ...

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Frequency of Eye Diseases in Subjects Aged 40 and Over. Open Journal of Ophthalmology, 15, 11-17. doi: ...

Northwestern University researchers have tested a method to reduce the dreaded nocturnal itch-scratch cycle. Using an ...